-
Product Insights
NewNet Present Value Model: Immatics NV’s IMA-203
Empower your strategies with our Net Present Value Model: Immatics NV's IMA-203 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Immatics NV’s IMA-201
Empower your strategies with our Net Present Value Model: Immatics NV's IMA-201 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: IO Biotech Inc’s (IO-102 + IO-103)
Empower your strategies with our Net Present Value Model: IO Biotech Inc's (IO-102 + IO-103) report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMA-201 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMA-201 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMA-201 in Ovarian Cancer Drug Details: IMA-201 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMA-201 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMA-201 in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMA-201 in Hepatocellular Carcinoma Drug Details: IMA-201 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMA-201 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMA-201 in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMA-201 in Sarcomas Drug Details: IMA-201 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMA-201 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMA-201 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMA-201 in Solid Tumor Drug Details: IMA-201 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – XT-150 in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XT-150 in Osteoarthritis Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XT-150 in Osteoarthritis Pain Drug Details: XT-150 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IM-19 in B-Cell Chronic Lymphocytic Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IM-19 in B-Cell Chronic Lymphocytic Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IM-19 in B-Cell Chronic Lymphocytic Leukemia Drug Details: IM-19 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fenebrutinib in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fenebrutinib in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fenebrutinib in Diffuse Large B-Cell Lymphoma Drug Details: Fenebrutinib...